Type:10 Tablets
Generic Name:Moxifloxacin
Manufacturer:NIPRO JMI Pharma Limited
Price:৳400.00
Community Acquired Pneumonia, Acute Bacterial Exacerbation of Chronic Bronchitis, Acute Bacterial Sinusitis, Complicated Intra-Abdominal Infection, Uncomplicated Skin and Skin Structure Infections, Complicated Skin and Skin Structure Infections, Typhoid Fever.
May be taken with or without food.
Oral The dose of Moxifloxacin is 400 mg once every 24 hours. The duration of therapy depends on the type of infection as described bellow Acute Bacterial Sinusitis 400 mg is given once daily for 10 days. Acute Bacterial Exacerbation of Chronic Bronchitis 400 mg is given once daily for 5 days. Community Acquired Pneumonia 400 mg is given once daily for 7-14 days. Uncomplicated Skin & Skin Structure infections 400 mg is given once daily for 7 days. Complicated Skin & Skin Structure infections 400 mg is given once daily for 7-21 days. Complicated Intra-Abdominal infections 400 mg is given once daily for 5-14 days. Typhoid Fever 400 mg is given once daily for 10-14 days.
<18 years: Safety and efficacy not established
Known hypersensitivity to moxifloxacin, other quinolones. Patients w/ known prolongation of QT interval, uncorrected hypokalaemia, myasthenia gravis. Concurrent use of class Ia (e.g.quinidine, procainamide, class III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents).
Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
Maintain adequate fluid intake; Patient w/ previous tendon disorders (e.g. rheumatoid arthritis), significant bradycardia or acute myocardial ischaemia, heart failure w/ reduced LVEF, known history of symptomatic arrhythmias, known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures; diabetes. Kidney, heart or lung transplant recipients. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and lightheadedness, if affected do not drive or operate machinery. Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid exposure to sunlight or artificial UV light (e.g. tanning beds, UVA/UVB treatment) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC and signs of infection.
1-10% Nausea (7%),Diarrhea (6%),Dizziness (3%),Decreased amylase (2%),Decreased basophils, eosinophils, hemoglobin, prothrombin time, red blood cells, neutrophils (2%),Decreased serum glucose (2%),Increased serum chloride (2%),Increased serum ionized calcium (2%),Immune hypersensitivity reaction (0.1-2%),Prolonged QT interval (0.1-2%) <1% Acute renal failure,Agranulocytosis,Anaphylactoid reaction,Aplastic anemia,Extrinsic allergic alveolitis,Hemolytic anemia,Hepatic failure,Hepatic necrosis,Hepatitis,Pancytopenia,Seizure,Serum sickness due to drug,Stevens-Johnson syndrome,Tendon rupture, tendinitis,Thrombocytopenia,Torsades de pointes,Toxic epidermal necrolysis
Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine. Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
